Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors

被引:65
作者
Facci, L
Stevens, DA
Pangallo, M
Franceschini, D
Skaper, SD
Strijbos, PJLM
机构
[1] GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England
[2] Univ Florence, Dept Pharmacol, I-50139 Florence, Italy
关键词
central nervous system neurons; apoptosis; phosphatidylinositol; 3-kinase; beta-amyloid; neuroprotection; glycogen synthase kinase-3;
D O I
10.1016/S0028-3908(03)00211-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Corticotropin-releasing factor (CRF) receptors are members of the superfamily of G-protein coupled receptors that utilise adenylate cyclase and subsequent production of cAMP for signal transduction in many tissues. Activation of cAMP-dependent pathways, through elevation of intracellular cAMP levels is known to promote survival of a large variety of central and peripheral neuronal populations. Utilising cultured primary rat central nervous system neurons, we show that stimulation of endogenous cAMP signalling pathways by forskolin confers neuroprotection, whilst inhibition of this pathway triggers neuronal death. CRF and the related CRF family peptides urotensin 1, urocortin, and sauvagine, which also induced cAMP production, prevented the apoptotic death of cerebellar granule neurons triggered by inhibition of phosphatidylinositol kinase-3 pathway activity with LY294002. These effects were negated by the highly selective CRF-R1 antagonist CP154,526. CRF even conferred neuroprotection when its application was delayed by up to 8 h following LY294002 addition. The CRF peptides also protected cortical and hippocampal neurons against death induced by beta-amyloid peptide (1-42), in a CRF-R1 dependent manner. In separate experiments, LY294002 reduced neuronal protein kinase B activity while increasing glycogen synthase kinase-3, whilst CRF (and related peptides) promoted phosphorylation of glycogen synthase kinase-3 without protein kinase B activation. Taken together, these results suggest that the neuroprotective activity of CRF may involve cAMP-dependent phosphorylation of glycogen synthase kinase-3. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:623 / 636
页数:14
相关论文
共 62 条
[1]   Mechanism of activation and function of protein kinase B [J].
Alessi, DR ;
Cohen, P .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (01) :55-62
[2]   The role of corticotropin-releasing factor in depression and anxiety disorders [J].
Arborelius, L ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
JOURNAL OF ENDOCRINOLOGY, 1999, 160 (01) :1-12
[3]   CHARACTERIZATION OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR-MEDIATED ADENYLATE-CYCLASE ACTIVITY IN THE RAT CENTRAL NERVOUS-SYSTEM [J].
BATTAGLIA, G ;
WEBSTER, EL ;
DESOUZA, EB .
SYNAPSE, 1987, 1 (06) :572-581
[4]   DISPLACEMENT OF CORTICOTROPIN-RELEASING FACTOR FROM ITS BINDING-PROTEIN AS A POSSIBLE TREATMENT FOR ALZHEIMERS-DISEASE [J].
BEHAN, DP ;
HEINRICHS, SC ;
TRONCOSO, JC ;
LIU, XJ ;
KAWAS, CH ;
LING, N ;
DESOUZA, EB .
NATURE, 1995, 378 (6554) :284-287
[5]   Cellular localization of corticotropin releasing factor receptors in the adult mouse cerebellum [J].
Bishop, GA ;
Seelandt, CM ;
King, JS .
NEUROSCIENCE, 2000, 101 (04) :1083-1092
[6]   DESENSITIZATION OF THE NMDA RECEPTOR COMPLEX BY GLYCINERGIC LIGANDS IN CEREBELLAR GRANULE CELL-CULTURES [J].
BOJE, KM ;
WONG, G ;
SKOLNICK, P .
BRAIN RESEARCH, 1993, 603 (02) :207-214
[7]   Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway [J].
Brar, BK ;
Jonassen, AK ;
Stephanou, A ;
Santilli, G ;
Railson, J ;
Knight, RA ;
Yellon, DM ;
Latchman, DS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8508-8514
[8]   Corticotrophin-releasing factor receptors: From molecular biology to drug design [J].
Chalmers, DT ;
Lovenberg, TW ;
Grigoriadis, DE ;
Behan, DP ;
DeSouza, EB .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (04) :166-172
[9]   IDENTIFICATION OF A 7 TRANSMEMBRANE HELIX RECEPTOR FOR CORTICOTROPIN-RELEASING FACTOR AND SAUVAGINE IN MAMMALIAN BRAIN [J].
CHANG, CP ;
PEARSE, RV ;
OCONNELL, S ;
ROSENFELD, MG .
NEURON, 1993, 11 (06) :1187-1195
[10]   Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: A centrally active corticotropin-releasing factor(1) receptor antagonist [J].
Chen, YL ;
Mansbach, RS ;
Winter, SM ;
Brooks, E ;
Collins, J ;
Corman, ML ;
Dunaiskis, AR ;
Faraci, WS ;
Gallaschun, RJ ;
Schmidt, A ;
Schulz, DW .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (11) :1749-1754